ALMDT Median Technologies

Completion of a Reserved Share Capital Increase of Median Technologies to FURUI of €19.6 Million at a €13 per Share Price

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--

Regulatory News:

Median Technologies (Paris:ALMDT), the Imaging Phenomics™ Company announced in a press release dated November 16th, 2016 that it had entered into an investment agreement with Furui Medical Science Company Luxembourg, a wholly owned subsidiary of Inner Mongolia Furui Medical Science Co., Ltd. (FURUI), according to which Median Technologies will issue and Furui Medical Science Company Luxembourg will subscribe 1,507,692 new ordinary shares of the company at a price of €13.00 per share representing a total amount of €19,599,996 through a reserved share capital increase.

Today, Median Technologies announces the completion of this share capital increase.

This share capital increase will allow Median Technologies mainly to develop business opportunities for China for the company’s products and also for general working capital and other general corporate purposes of the company.

After completion of this transaction, the share capital of Median Technologies is 579,601.30 euros and the total number of shares is 11,592,026 representing 11,575,006 voting rights.

The newly issued shares are assimilated to the existing ordinary shares of the company and listed on Alternext on the same listing line of the existing shares under ISIN Code: FR0011049824. After completion of the transaction, Furui Medical Science Company Luxembourg holds 13.01% of the share capital and 13.03% of the voting rights of Median Technologies.

The original version of this press release is the French version. This version is a translation and should in no way be considered official. The original French version shall prevail over this translation in English. The translation must always be construed according to the original version in French.

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics™ to provide insights into novel therapies and treatment strategies. Our unique solutions, LMS for lesion management and our imaging phenotyping system iBiopsy™, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to bring new treatments to patients in need more precisely, quicker and with an eye on reducing overall care costs. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017.

EN
19/12/2016

Underlying

ALMDTMedian Technologies

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Median Technologies

Free Trial
ALMDT Median Technolo...

Median Technologies: 1 director

A director at Median Technologies sold 14,000 shares at 3.161EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

ALMDT MEDIAN TECHNOLOGIES
09/12/25 September 12, 2025 1 EN
Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: EUR23.5m capital raise extends runway into Q4 202...

Median Technologies successfully secured a capital raise via ABSA of EUR23.5m in total gross proceeds, priced at EUR1.66 (at ~18% discount to 20-day VWAP). The offering was oversubscribed, surpassing the initial EUR22m target, with 64% backed by existing shareholders, 2% by a public offering in Fra

ALMDT MEDIAN TECHNOLOGIES
08/04/25 August 4, 2025 1 EN
Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: Launch of EUR22m capital increase to unlock EIB f...

Median Technologies has launched a EUR22m capital increase via a public offering of shares with warrants (ABSA), priced at EUR1.66 (at ~18% discount to 20-day VWAP), with 78% of the deal already secured via existing and new investors. The raise aimed to i) meet the drawing conditions of the Tranche

ALMDT MEDIAN TECHNOLOGIES
07/22/25 July 22, 2025 1 EN
Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: EIB loan signed, tied to equity raise and debt re...

Friday post-market, Median announced the final sign of the EIB loan agreement of EUR37.5m, which has been structured in three tranches (EUR19m, EUR8.5m, EUR10m) and with several key conditions being set to access the first one. These include i) a capital increase of at least EUR16m (including issua

ALMDT MEDIAN TECHNOLOGIES
07/14/25 July 14, 2025 1 EN
Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: CE mark filing keep eyonis on track, US launch be...

Yesterday post-market, Median announced that it has submitted the Class IIb CE marking filing for eyonis LCS, just a month after the FDA 510(k) submission, precisely sticking to the company's timeline guidance. Our confidence in a positive outcome remains high, as both submissions are underpinned b

ALMDT MEDIAN TECHNOLOGIES
07/02/25 July 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch